Meeting
2019 Gastrointestinal Cancers Symposium
Expanded RAS and BRAF V600 testing as predictive biomarkers for single agent cetuximab in the randomized phase III CO.17 trial.
Authors
Jonathan M. Loree
BC Cancer, Vancouver, BC, Canada
Jonathan M. Loree , Anthony Dowers , Dongsheng Tu , Christopher J. O'Callaghan , Dan Edelstein , Hannah Quinn , Derek J. Jonker , Chris Karapetis , Timothy Jay Price , John Raymond Zalcberg , Malcolm J. Moore , Paul Michael Waring , Hagen F. Kennecke , Stanley R. Hamilton , Scott Kopetz
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Cancers of the Colon, Rectum, and Anus
Sub Track
Translational Research
Clinical Trial Registration Number
NCT00079066
Citation
J Clin Oncol 37, 2019 (suppl 4; abstr 537)
DOI
10.1200/JCO.2019.37.4_suppl.537
Abstract #
537
Poster Bd #
E20
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
Influence of KRAS exon 2 mutation variants as well as NRAS- and BRAF-mutations on outcome of patients with metastatic colorectal cancer (mCRC) receiving combination chemotherapy with or without bevacizumab.
First Author: Dominik Paul Modest
Poster
2016 ASCO Annual Meeting
Association of right-sided colon cancer with poor efficacy of cetuximab in patients with RAS wild-type metastatic colorectal cancer.
First Author: Dalyong Kim
Poster
2013 ASCO Annual Meeting
Comprehensive analysis of KRAS and NRAS mutations as predictive biomarkers for single agent panitumumab (pmab) response in a randomized, phase III metastatic colorectal cancer (mCRC) study (20020408).
First Author: Scott D. Patterson
Poster
2016 ASCO Annual Meeting
Final results from a phase III trial evaluating panitumumab (pmab) + best supportive care (BSC) vs BSC in chemorefractory wild-type (WT) KRAS exon 2 and WT RAS metastatic colorectal cancer (mCRC).
First Author: Tae Won Kim